Mixed Deck — All CSP Topics Flashcards

What is the primary function of a specialty pharmacy's patient assistance program (PAP) coordination service?

Answer: To help financially eligible patients access free or reduced-cost specialty medications from manufacturers

PAP coordination connects patients who meet manufacturer income and insurance eligibility criteria with free or reduced-cost medication programs to eliminate financial barriers to specialty therapy.

Which of the following activities by a specialty pharmacy is the clearest example of potential healthcare fraud?

Answer: Billing an insurer for a brand-name drug using a 'Dispense as Written' code when the generic equivalent was dispensed.

Fraud involves intentional deception for financial gain. Billing for a more expensive brand-name product when a cheaper generic was dispensed is a form of upcoding and a clear violation. The other options describe legitimate, and often required, functions of a specialty pharmacy: utilizing patient assistance programs, performing clinical management, and promoting adherence.

A patient with rheumatoid arthritis, who has failed methotrexate monotherapy, is being started on a Janus kinase (JAK) inhibitor. Which of the following represents a class-wide black box warning for JAK inhibitors that the specialty pharmacist must counsel the patient on?

Answer: Increased risk of serious infections, malignancy, and thrombosis

The FDA has required a class-wide black box warning for Janus kinase (JAK) inhibitors used for chronic inflammatory conditions. This warning includes an increased risk of serious infections, malignancies (like lymphoma and lung cancer), major adverse cardiovascular events (MACE), and thrombosis. While other warnings exist for different drug classes, this specific combination of risks is characteristic of the JAK inhibitor class warning.

Under most REMS programs with ETASU, a specialty pharmacy may NOT dispense a REMS medication if which condition exists?

Answer: The prescriber is not enrolled in the REMS program

If a REMS program requires prescriber certification, a pharmacy cannot legally dispense the medication unless the prescriber is enrolled and authorized under that REMS.

What does the Controlled Substances Act (CSA) regulate?

Answer: It regulates controlled substances to prevent misuse and abuse

The Controlled Substances Act (CSA) is a federal law that categorizes drugs based on their potential for abuse and medical utility. It establishes a regulatory framework for the manufacture, distribution, and dispensing of controlled substances. The CSA aims to prevent their diversion, misuse, and abuse, thereby protecting public health and safety.

What does the term 'hub services' refer to in specialty pharmacy?

Answer: Manufacturer-sponsored programs providing patient support, benefits investigation, and PA assistance

Hub services are manufacturer-sponsored patient support programs that assist with benefits verification, prior authorization, copay assistance, and patient education for specific specialty products.

What is a common method used in pharmacoeconomics to assess the economic burden of a disease?

Answer: Using Quality-Adjusted Life Years (QALYs)

Quality-Adjusted Life Years (QALYs) are a common metric used in pharmacoeconomics to measure the health outcomes of interventions, taking into account both the quantity and quality of life. A QALY combines the years of life gained from a treatment with a weighting for the quality of those years, where 1 QALY equals one year of perfect health. This allows for a standardized comparison of the economic burden and effectiveness of different diseases and treatments.

A patient's commercial insurance plan utilizes a 'copay accumulator' program. The patient uses a manufacturer's copay card, which covers their $400 monthly cost for a specialty drug. What is the primary consequence of this program for the patient?

Answer: The $400 paid by the manufacturer will not count toward the patient's annual deductible or out-of-pocket maximum.

Copay accumulator programs are designed by payers to prevent the value of manufacturer copay assistance from counting toward a patient's deductible and annual out-of-pocket maximum. The plan 'accumulates' the manufacturer's payments but does not credit them to the patient's cost-sharing responsibilities, often resulting in an unexpected high cost for the patient once the manufacturer's assistance is exhausted.

What is the role of motivational interviewing in patient counseling?

Answer: It helps patients make informed choices by addressing their motivations

Motivational interviewing is a patient-centered counseling approach that helps individuals explore and resolve ambivalence about behavior change. In pharmacy, it empowers patients to identify their own reasons for adhering to therapy or making lifestyle changes, fostering intrinsic motivation rather than imposing solutions. This collaborative approach leads to more sustainable and informed health decisions.

Which government agency enforces drug safety regulations in the United States?

Answer: Food and Drug Administration (FDA)

The Food and Drug Administration (FDA) is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices. It rigorously evaluates new drugs before they can be marketed and monitors their safety once approved, making it the primary enforcer of drug safety regulations.

What is the role of a pharmacist in educating patients about new medications?

Answer: Providing clear instructions on the use of medications

Pharmacists are the medication experts and play a vital role in educating patients about new medications. This includes explaining the drug's purpose, proper dosage, administration technique, potential side effects, and important drug interactions. Clear, comprehensive instructions ensure patients understand how to use their medication safely and effectively, maximizing therapeutic benefits and minimizing risks.

A physician's office faxes a specialty prescription to the pharmacy, but it is missing the patient's insurance information and diagnosis code. What is the most appropriate next action for the intake coordinator?

Answer: Proactively contact the prescriber's office to obtain the complete and accurate information.

To ensure timely initiation of therapy and avoid delays, the specialty pharmacy team should proactively reach out to the prescriber's office to clarify and obtain any missing information, such as diagnosis codes or insurance details. This collaborative approach is a key service provided by specialty pharmacies to support both patients and providers. Rejecting the prescription or placing the burden entirely on the patient would create unnecessary delays.

Which term describes a REMS requirement that restricts dispensing to only specially certified pharmacies?

Answer: Restricted distribution system

A restricted distribution system is an ETASU element that limits dispensing to certified specialty pharmacies, preventing dispensing at retail or non-enrolled outlets.

A specialty pharmacist is dispensing a medication for which the patient's insurance has issued a prior authorization denial. The denial states 'step therapy requirements not met.' Which of the following is the most appropriate next step for the pharmacist to take?

Answer: Contact the prescriber to discuss the denial and assist in appealing or providing clinical rationale for the prescribed drug.

When a prior authorization is denied due to step therapy, it means the insurer requires the patient to try one or more preferred, often lower-cost, alternative medications first. The specialty pharmacist's role is to collaborate with the prescriber. This involves communicating the reason for denial and working with the prescriber's office to either submit an appeal with clinical justification for bypassing step therapy (e.g., contraindication, history of failure with the preferred agent) or to select an appropriate alternative.

According to the 2021 IDSA/SHEA guidelines for an initial episode of non-severe Clostridioides difficile infection (CDI), which of the following is the preferred treatment?

Answer: Fidaxomicin 200 mg orally twice daily for 10 days

The 2021 focused update from IDSA/SHEA suggests using fidaxomicin over a standard course of vancomycin for an initial CDI episode. This is a conditional recommendation based on moderate certainty of evidence, placing a high value on fidaxomicin's beneficial effects, though vancomycin remains an acceptable alternative.

What is the primary challenge in managing patients on specialty drug therapies?

Answer: Ensuring adherence, managing side effects, and cost

Specialty drug therapies are often complex, expensive, and associated with significant side effects, making patient adherence a major challenge. Specialty pharmacists must address these multifaceted issues by providing extensive patient education, support for side effect management, and assistance with financial burdens. These three factors are consistently identified as primary hurdles to successful treatment outcomes.

What is the primary consequence for a specialty pharmacy that dispenses a REMS-required medication without complying with REMS requirements?

Answer: The pharmacy may face FDA enforcement action, including warning letters, injunctions, or civil monetary penalties

Non-compliance with REMS requirements can subject a pharmacy to FDA enforcement actions including warning letters, injunctions, seizures, and civil monetary penalties.

A specialty pharmacist is counseling a patient who expresses ambivalence about starting a new oral medication for multiple sclerosis due to a fear of potential side effects. Which of the following statements best exemplifies the use of Motivational Interviewing (MI)?

Answer: "It sounds like you're concerned about how the side effects might impact your daily life, but you're also hopeful this could prevent a relapse. Could we talk more about that balance?"

This statement uses a key MI technique called a "double-sided reflection." It acknowledges and validates the patient's concerns (the "con" of taking the medication) while also reflecting their potential motivation for taking it (the "pro"), encouraging them to explore their own ambivalence without judgment or confrontation.

Which of the following specialty pharmacy services is MOST critical for ensuring patient access to ultra-high-cost gene therapies such as betibeglogene spartacus (Zynteglo) for beta-thalassemia?

Answer: Outcomes-based contracting facilitation and manufacturer financial assistance coordination

Gene therapies with multi-million-dollar price tags require specialty pharmacies to navigate outcomes-based contracts and manufacturer assistance programs to make therapy financially feasible for payers and patients.

A patient with phenylketonuria (PKU) is prescribed sapropterin (Kuvan). What is the standard method to assess response to this therapy?

Answer: Blood phenylalanine level measured after a 1-month therapeutic trial

Response to sapropterin is determined by measuring blood phenylalanine levels after a 1-month trial; only patients who respond (defined as a ≥30% reduction in phenylalanine) should continue therapy.